Intervention Protocol

You have free access to this content

Selective estrogen receptor modulators for preventing and treating postmenopausal osteoporosis

  1. Wenjuan Li1,
  2. Jing Zhang2,
  3. Liangzhi Xu1,*,
  4. Liulin Tang1,
  5. Xin Pan3,
  6. Taixiang Wu4

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 20 FEB 2014

DOI: 10.1002/14651858.CD010977


How to Cite

Li W, Zhang J, Xu L, Tang L, Pan X, Wu T. Selective estrogen receptor modulators for preventing and treating postmenopausal osteoporosis (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD010977. DOI: 10.1002/14651858.CD010977.

Author Information

  1. 1

    West China Second University Hospital, West China Women's and Children's Hospital, Department of Obstetrics and Gynecology, Chengdu, Sichuan, China

  2. 2

    West China Second University Hospital, Sichuan University, Department of Obstetrics and Gynecology, Chengdu, Sichuan, China

  3. 3

    The University of Newcastle, Mother and Baby Center, School of Medicine and Public Health, New Castle, New South Wales, China

  4. 4

    West China Hospital, Sichuan University, Chinese Clinical Trial Registry, Chinese Ethics Committee of Registering Clinical Trials, Chengdu, Sichuan, China

*Liangzhi Xu, Department of Obstetrics and Gynecology, West China Second University Hospital, West China Women's and Children's Hospital, No. 17, Section Three, Ren Min Nan Lu Avenue, Chengdu, Sichuan, 610041, China. liangzxu@126.com.

Publication History

  1. Publication Status: New
  2. Published Online: 20 FEB 2014

SEARCH

References

Additional references

Atkins 2004
  • Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ (Clinical Research Ed.) 2004;328(7454):1490. [PUBMED: 15205295]
Avenell 2009
Barrett-Connor 2002
  • Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287(7):847-57. [PUBMED: 11851576]
Bodine 1998
  • Bodine PV, Henderson RA, Green J, Aronow M, Owen T, Stein GS, et al. Estrogen receptor-alpha is developmentally regulated during osteoblast differentiation and contributes to selective responsiveness of gene expression. Endocrinology 1998;139(4):2048-57. [PUBMED: 9528993]
Bord 2001
  • Bord S, Horner A, Beavan S, Compston J. Estrogen receptors alpha and beta are differentially expressed in developing human bone. Journal of Clinical Endocrinology and Metabolism 2001;86(5):2309-14. [PUBMED: 11344243]
Bryant 1999
  • Bryant HU, Glasebrook AL, Yang NN, Sato M. An estrogen receptor basis for raloxifene action in bone. Journal of Steroid Biochemistry and Molecular Biology 1999;69(1-6):37-44. [PUBMED: 10418979]
Chi 2012
  • Chi F, Wu R, Zeng Y, Xing R, Liu Y, Xu Z. Effects of toremifene versus tamoxifen on breast cancer patients: a meta-analysis. Breast Cancer 2012;Dec:1-12. [DOI: 10.1007/s12282-012-0430-6]
Cummings 1999
  • Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281(23):2189-97. [PUBMED: 10376571]
Cummings 2002
Egger 1997
Grady 2004
  • Grady D, Ettinger B, Moscarelli E, Plouffe L, Jr, Sarkar S, Ciaccia A, et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstetrics and Gynecology 2004;104(4):837-44.
Grossman 2001
Haguenauer 2010
  • Haguenauer D, Shea B, Tugwell P, Wells GA, Welch V. Fluoride for treating postmenopausal osteoporosis. Cochrane Database of Systematic Reviews 2010, Issue 7. [DOI: 10.1002/14651858.CD002825]
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hodgson 2003
  • Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocrine Practice 2003;9(6):544-64.
Hong 2011
  • Hong L, Zhang G, Sultana H, Yu Y, Wei Z. The effects of 17-beta estradiol on enhancing proliferation of human bone marrow mesenchymal stromal cells in vitro. Stem Cells and Development 2011;20(5):925-31. [PUBMED: 20735179]
Johnell 2005
Kanis 1994
Kanis 1994a
  • Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporosis International 1994;4(6):368-81. [PUBMED: 7696835]
Kanis 2003
  • Kanis JA, Johnell O, Black DM, Downs RW, Jr, Sarkar S, Fuerst T, et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 2003;33(3):293-300.
Ke 1995
  • Ke HZ, Simmons HA, Pirie CM, Crawford DT, Thompson DD. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology 1995;136(6):2435-41. [PUBMED: 7750465]
Kumar 1988
Lau 2006
Levis 2012
  • Levis S, Theodore G. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report. Journal of Managed Care Pharmacy 2012;18(4 Suppl B):S1-15.
Lewiecki 2004
  • Lewiecki EM. Management of osteoporosis. Clinical and Molecular Allergy 2004;2(1):9. [PUBMED: 15253771]
Lippman 2006
  • Lippman ME, Cummings SR, Disch DP, Mershon JL, Dowsett SA, Cauley JA, et al. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clinical Cancer Research 2006;12(17):5242-7. [PUBMED: 16951244]
Looker 1998
  • Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporosis International 1998;8(5):468-89. [PUBMED: 9850356]
Morello 2003
Moskovic 2012
Murad 2012
  • Murad MH, Drake MT, Mullan RJ, Mauck KF, Stuart LM, Lane MA, et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. Journal of Clinical Endocrinology and Metabolism 2012;97(6):1871-80.
Nachtigall 2011
  • Nachtigall MJ, Jessel RH, Flaumenhaft R, Nachtigall R, Yoles I, Naftolin F, et al. The selective estrogen receptor modulator DT56a (Femarelle) does not affect platelet reactivity in normal or thrombophilic postmenopausal women. Menopause 2011;18(3):285-8.
NAMS 2010
  • North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause (New York, N.Y.) 2010;17(1):25-54. [PUBMED: 20061894]
Okazaki 2002
  • Okazaki R, Inoue D, Shibata M, Saika M, Kido S, Ooka H, et al. Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER) alpha or beta. Endocrinology 2002;143(6):2349-56. [PUBMED: 12021200]
RevMan 2012 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Riggs 2003
Santen 2011
Schünemann 2011
  • Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. [Available from www.cochrane-handbook.org]
Shelly 2008
  • Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Selective estrogen receptor modulators: an update on recent clinical findings. Obstetrical & Gynecological Survey 2008;63(3):163-81. [PUBMED: 18279543]
Shelly 2008a
  • Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Selective estrogen receptor modulators: an update on recent clinical findings. Obstetrical and Gynecological Survey 2008;63(3):163-81.
Singh 2001
Siris 2002
  • Siris E, Adachi JD, Lu Y, Fuerst T, Crans GG, Wong M, et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International 2002;13(11):907-13.
Waters 2001
  • Waters KM, Rickard DJ, Riggs BL, Khosla S, Katzenellenbogen JA, Katzenellenbogen BS, et al. Estrogen regulation of human osteoblast function is determined by the stage of differentiation and the estrogen receptor isoform. Journal of Cellular Biochemistry 2001;83(3):448-62. [PUBMED: 11596113]
Wells 2008a
  • Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD001155.pub2]
Wells 2008b
  • Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD003376.pub3]
Wells 2008c
  • Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD004523.pub3]
Yoles 2004
  • Yoles I, Yogev Y, Frenkel Y, Hirsch M, Nahum R, Kaplan B. Efficacy and safety of standard versus low-dose Femarelle (DT56a) for the treatment of menopausal symptoms. Clinical and Experimental Obstetrics & Gynecology 2004;31(2):123-6.